Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 285

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 285
---
.

Market
Opportunity

Telomir-1
is under investigation for its therapeutic potential across multiple areas, including Progeria, Type 2 Diabetes, Wilson’s
disease, Age-related Macular Degeneration (AMD), Alzheimer’s disease, cancer, and other age-related conditions. Additionally,
Telomir-1 is being explored for its potential in mitigating the severity of viral infections such as avian influenza (bird flu) by
addressing oxidative stress and immune dysfunction. These indications are being carefully evaluated to identify the most impactful
opportunities for clinical development and market entry.

The
market potential for these conditions is substantial across the United States, Canada, and Mexico. The Type 2 Diabetes market in the
U.S. alone was valued at approximately $30.47 billion in 2022, according to Fortune Business Insights, driven by rising prevalence and demand
for advanced therapies. The global AMD market is projected to reach $18 billion by 2030, growing at a CAGR of 8.2% from 2024 to 2030.
Alzheimer’s disease, one of the most pressing age-related conditions, is projected to grow significantly, with the global market
expected to reach $13 billion by 2031, according to Allied Market Research, fueled by increasing diagnoses and advancements in treatments
targeting cognitive decline.

The U.S oncology market,
covering a broad range of cancers, was valued at $74.1 billion in 2023, and is projected to reach $180.12 billion by 2033, growing at
a CAGR of 9.2% from 2024 to 2033, as per Precedence Research. Meanwhile, the anti-aging and age-reversal market was valued at $91.05
billion in 2024 globally and is projected to grow to $160.24 billion globally by 2031, with a CAGR of 7.32%, according to Verified Market
Research.

Rare
diseases such as Progeria and Wilson’s disease, despite having smaller patient populations, represent highly lucrative
opportunities due to significant unmet medical needs and strong pricing potential. For instance, the annual treatment cost for
Progeria exceeds $1 million, based on the price of Zokinvy (lonafarnib), the FDA-approved drug for the condition. Similarly,
treatments for Wilson’s disease, like Syprine (trientine hydrochloride), can cost approximately